Literature DB >> 17223502

Pulmonary vascular abnormalities in cirrhosis.

Philippe Herve1, Jerome Le Pavec, Benjamin Sztrymf, Benoit Decante, Laurent Savale, Olivier Sitbon.   

Abstract

Two pulmonary vascular disorders can occur in liver disease and/or portal hypertension: the hepatopulmonary syndrome (HPS), which is characterized by intrapulmonary vascular dilatations, and portopulmonary hypertension (POPH), in which pulmonary vascular resistance is elevated. POPH and HPS are characterized by distinct pulmonary microvascular remodelling, which occurs at different anatomical sites of the pulmonary microcirculation. The exact pathophysiological mechanisms of these pulmonary vascular disorders are unknown. However, as HPS and POPH have been reported in patients with extrahepatic portal hypertension, the factor that determines their development must be portal hypertension. The clinical presentations are very different, with gas exchange impairment in HPS and hemodynamic failure in POPH. The severity of HPS seems to parallel the severity of liver failure, whereas no simple relationship has been identified between hepatic impairment and the severity of POPH. Resolution of HPS is common after liver transplantation, which has an uncertain effect in POPH.

Entities:  

Mesh:

Year:  2007        PMID: 17223502     DOI: 10.1016/j.bpg.2006.07.011

Source DB:  PubMed          Journal:  Best Pract Res Clin Gastroenterol        ISSN: 1521-6918            Impact factor:   3.043


  12 in total

1.  Hepatopulmonary syndrome in children with cirrhotic and non-cirrhotic portal hypertension: a single-center experience.

Authors:  Sinan Sari; Deniz Oguz; Tugba Sucak; Buket Dalgic; Tamer Atasever
Journal:  Dig Dis Sci       Date:  2011-07-27       Impact factor: 3.199

2.  Hepatoma-derived growth factor is associated with pulmonary vascular remodeling and PAH disease severity and survival.

Authors:  Jun Yang; Anjira S Ambade; Melanie Nies; Megan Griffiths; Rachel Damico; Dhananjay Vaidya; Stephanie Brandal; Michael W Pauciulo; Katie A Lutz; Anna W Coleman; William C Nichols; Eric D Austin; Dunbar Ivy; Paul M Hassoun; Allen D Everett
Journal:  Pulm Circ       Date:  2022-03-07       Impact factor: 2.886

3.  Genetic risk factors for portopulmonary hypertension in patients with advanced liver disease.

Authors:  Kari E Roberts; Michael B Fallon; Michael J Krowka; Robert S Brown; James F Trotter; Inga Peter; Hocine Tighiouart; James A Knowles; Daniel Rabinowitz; Raymond L Benza; David B Badesch; Darren B Taichman; Evelyn M Horn; Steven Zacks; Neil Kaplowitz; Steven M Kawut
Journal:  Am J Respir Crit Care Med       Date:  2009-02-12       Impact factor: 21.405

4.  Radiological findings in a case of multiple focal nodular hyperplasia associated with portal vein atresia and portopulmonary hypertension.

Authors:  In Joon Lee; Sook-Hyang Jeong; Jin Woo Choi; Hee Sun Park; Kyoung Ho Lee; Haeryoung Kim
Journal:  Korean J Radiol       Date:  2008 Jul-Aug       Impact factor: 3.500

5.  Clinical risk factors for portopulmonary hypertension.

Authors:  Steven M Kawut; Michael J Krowka; James F Trotter; Kari E Roberts; Raymond L Benza; David B Badesch; Darren B Taichman; Evelyn M Horn; Steven Zacks; Neil Kaplowitz; Robert S Brown; Michael B Fallon
Journal:  Hepatology       Date:  2008-07       Impact factor: 17.425

Review 6.  Cirrhosis and hepatopulmonary syndrome.

Authors:  Gokhan Tumgor
Journal:  World J Gastroenterol       Date:  2014-03-14       Impact factor: 5.742

Review 7.  Inflammation: a way to understanding the evolution of portal hypertension.

Authors:  María-Angeles Aller; Jorge-Luis Arias; Arturo Cruz; Jaime Arias
Journal:  Theor Biol Med Model       Date:  2007-11-13       Impact factor: 2.432

Review 8.  The mast cell integrates the splanchnic and systemic inflammatory response in portal hypertension.

Authors:  María-Angeles Aller; Jorge-Luis Arias; Jaime Arias
Journal:  J Transl Med       Date:  2007-09-24       Impact factor: 5.531

9.  Low serum levels of alpha1 anti-trypsin (α1-AT) and risk of airflow obstruction in non-primary α1-AT-deficient patients with compensated chronic liver disease.

Authors:  Elizabeth Rodríguez-Romero; Juan Antonio Suárez-Cuenca; César Iván Elizalde-Barrera; Paul Mondragón-Terán; José Enrique Martínez-Hernández; Eduardo Gómez-Cortés; Rebeca Pérez-Cabeza de Vaca; Rolando E Hernández-Muñoz; Alberto Melchor-López; Nayeli Gabriela Jiménez-Saab
Journal:  Med Sci Monit       Date:  2015-04-27

Review 10.  Hepatopulmonary Syndrome and Liver Transplantation: A Recent Review of the Literature.

Authors:  Caglar Cosarderelioglu; Arif M Cosar; Merve Gurakar; Nabil N Dagher; Ahmet Gurakar
Journal:  J Clin Transl Hepatol       Date:  2016-03-15
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.